bortezomib + pentostatin + rituximab

This is a combination regimen of three drugs used primarily in the treatment of hematologic malignancies, particularly B-cell lymphomas and related disorders. **Bortezomib** is a small molecule proteasome inhibitor that disrupts the 26S proteasome, leading to apoptosis in cancer cells by interfering with protein degradation pathways[4]. **Pentostatin** is a purine analog and adenosine deaminase inhibitor that interferes with DNA synthesis, resulting in cytotoxicity especially in lymphocytes. **Rituximab** is a chimeric monoclonal antibody targeting CD20 on B-cells, leading to cell lysis via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity[3]. The combination leverages complementary mechanisms—proteasome inhibition, DNA synthesis inhibition, and targeted B-cell depletion—to enhance antitumor activity. This regimen has been explored for relapsed or refractory mantle cell lymphoma and other B-cell malignancies.

Other names

PS341 (for bortezomib)2'-deoxycoformycin (for pentostatin)anti-CD20 monoclonal antibody (for rituximab)